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Abstract 
Cancer cells do not grow as an isolated homogeneous mass; tumours are, in fact, complex and 
heterogeneous collections of cancer and surrounding stromal cells, collectively termed the tumour 
microenvironment. The interaction between cancer cells and stromal cells in the tumour 
microenvironment has emerged as a key concept in the regulation of cancer progression. 
Understanding the intercellular dialogue in the tumour microenvironment is therefore an important 
goal. One aspect of this dialogue which has not been appreciated until recently is the role of 
extracellular vesicles (EVs). EVs are small vesicles released by cells under both normal and 
pathological conditions; they can transfer biological molecules between cells leading to changes in 
phenotype. EVs have emerged as important regulators of biological processes and can be 
dysregulated in diseases such as cancer; rapidly growing interest in their biology and therapeutic 
potential led to the Royal Society hosting a Scientific Meeting to explore the roles of EVs in the 
tumour microenvironment. This cross-disciplinary meeting explored examples of how aberrant 
cross-talk between tumour and stromal cells can promote cancer progression, and how such 
signalling can be targeted for diagnostic, prognostic and therapeutic benefit. In this review, and the 
special edition of Philosophical Transactions of the Royal Society B that follows, we will provide an 
overview of the content and outcomes of this exciting meeting. 
 
Introduction 
Cancer is a nefarious disease that claims millions of victims around the world each year [1]. 
Improvements in treatment have increased the overall survival rates, particularly for some tumour 
types but, despite decades of intensive research, some forms of cancer remain frequently refractory 
to curative therapy [2]. Several factors contribute to this, including: 1. The heterogeneous nature of 
tumours, both between patients and within the tumour mass itself [3], 2. The tendency for tumours 
to evolve and adapt to change in their environment, for example giving them the ability to become 
resistant to drugs [4], and 3. The propensity of cancer cells to metastasise to local and distant sites, 
which is ultimately what normally kills the patient [5]. The need for further research into cancer is 
therefore greater than ever. 
Our opening paragraph paints a rather bleak picture of cancer research and treatment. However, 
our efforts as a community have yielded countless breakthroughs in our understanding of what 
drives cancer development and progression. One important concept that has only recently gained 
broad acceptance is the role of the tumour microenvironment (TME) [6]. Cancer cells do not exist in 
isolation, but rather they coexist with normal cells in the body. Indeed, a multitude of non-cancer 
cells can be found throughout the mass of the tumour, collectively termed the tumour 
microenvironment. In this way tumours are as complex, if not more so, than any healthy organ in the 
body. Non-tumour cells that reside in the cancer mass include cancer associated fibroblasts (CAFs) 
and tumour associated macrophages (TAMs) (figure 1), as well as other immune cells and 
endothelial cells embedded in the extracellular matrix (ECM). The interaction between these cells 
and the tumour are generally accepted to be of crucial importance, but the nature of the 
interactions, and how they may be disrupted, remains poorly understood. Cells and non-cellular 
components of the TME are thought to sustain the tumour and can add to the heterogeneity, 
adaptability and metastatic ability of cancer [7]. Indeed, they can contribute to most, if not all, 
aspects of tumour progression. Understanding the tumour microenvironment is therefore of key 
importance if we are to make genuine breakthroughs in cancer treatment. 
Extracellular vesicles (EVs) are another relatively new concept in cancer biology. EVs were 
discovered many years ago, but the realisation that they are not simply a waste disposal system and 
that they play important roles in various biological processes only occurred in the last few years [8]. 
EVs are small lipid-enclosed vesicles that are released by cells into the extracellular space. Several 
types of EV are produced by cells, and the nomenclature depends on the method of their biogenesis 
(figure 2). Exosomes are EVs produced when multivesicular bodies (MVBs) fuse with the plasma 
membrane, releasing the intraluminal vesicles they carry out of the cell [9]. Microvesicles are 
another class of EV which are formed by outward budding of the plasma membrane [9]. Apoptotic 
bodies are EVs released by cells undergoing apoptosis [9]. EVs can carry a variety of cargo, including 
lipids, proteins, coding and non-coding RNA, and even DNA. EVs released by one cell can be taken up 
by another cell, leading to the transfer of macromolecules from a donor cell to a recipient cell [10]. 
This can be associated with the regulation of important phenotypic changes in the recipient cell. 
Indeed, EVs have been shown to have important roles in a range of biological roles [11]. Thus, EVs 
are emerging as an important part of the molecular dialogue between cells in a complex organism. 
Given their importance in communication between cells it is reasonable to hypothesise that EVs 
could mediate crucial interactions between cells in the tumour microenvironment. A number of 
studies have begun to address this question, and it is indeed emerging that cancer cells and non-
malignant cells can exchange EVs. This reciprocal transfer of EVs can play an important role in 
promoting cancer progression [12]. Therefore, we must try to characterise and understand the roles 
and mechanisms of EV-mediated communication in the tumour microenvironment, an endeavour 
which should also yield new therapeutic targets for the treatment for cancer. Given the nascent 
state of the field and the potential therapeutic rewards it would seem sensible to bring together 
researchers in these two fields, EVs and the tumour microenvironment, to discuss the potential 
synergies and seed new collaborations. For these reasons the Royal Society hosted a Scientific 
Meeting on the topic of ‘Extracellular Vesicles in the Tumour Microenvironment’. The meeting was 
held on the 23rd and 24th of January 2017 at the Royal Society’s historic headquarters in London. 
The meeting was well attended, with over 160 scientists at all levels, from undergraduate to group 
leaders, from clinicians to enthusiastic members of the public. Leading experts from across the globe 
were invited to present their cutting-edge work in these fields, and a vibrant poster session was 
held. There were many opportunities for interaction with presenters, including during an active 
discussion in the final session in which some of the challenges of working on EVs in the tumour 
microenvironment were debated. Here we will summarise some of the key messages and try to 
reflect the excitement of the meeting, as well as introducing the work submitted by some of the 
speakers to this special edition of Philosophical Transactions of the Royal Society B. 
New methodology for studying EVs in the tumour microenvironment The field of extracellular 
vesicles is relatively new and the best methodology for studying them is still being established. 
Technical challenges such as their small size, heterogeneity and paucity of molecular content makes 
them particularly difficult to study. This difficulty was reflected in several of the discussions through 
the meeting. However, interesting new findings and methodologies are emerging which will help to 
push the field forward. For example, Victoria James (Nottingham University, UK) described a method 
for analysing the nature of vesicular RNA taken up by recipient cells. This will help in the deciphering 
exactly what RNA species are passed between cells in EVs. 
Using this technique Dr James described how vesicular transfer can occur between prostate cancer 
cells and bone cells (osteoblasts). 
Microscopy is a key area that needs to be developed for improved imaging of EVs. Michiel Pegtel (VU 
University Medical Center Amsterdam) and Dr James Edgar (University of Cambridge) both 
presented exquisite images of EVs being released by cells. Dr Pegtel presented a novel fluorescent 
construct of CD63 (a known EV protein marker) which could be imaged by total internal reflection 
fluorescence (TIRF) microscopy. Dr Edgar used a combination of techniques including electron 
microscopy to show that exosomes are tethered to the membrane of MVBs via tetherin, and these 
exosomes often remain bound to the plasma membrane after the MVB fuses at the cell surface. 
Knocking down tetherin increased the release of exosomes into the extracellular space [13]. Tuula 
Salo (University of Helsinki) has developed a novel alternative to Matrigel (a product used to mimic 
extracellular matrix that is often used in experiments to measure the invasive properties of cancer 
cells) [14]. Using this material, myogel, she showed that EVs can induce invasive ability when placed 
onto recipient cells. 
 
EV heterogeneity 
Another important issue in the study of EVs is that of heterogeneity. EVs prepared with most 
commonly used methodologies are heterogeneous in nature. Any biological effects of the total 
population of EVs is a result of the overall combined effect of the different subtypes present; 
however, as results are often conflicting in the literature (and sometimes within studies) it is 
important to delve deeper into the population of EVs to look for subtype-specific functions. The 
potential biological roles of different subtypes of EVs within a heterogeneous mix are largely 
unknown, but insights are beginning to emerge from important studies. Deborah Goberdhan 
(University of Oxford) presented her exciting results on different subtypes of EVs. She showed that 
inhibiting a glutamine-sensing transporter affected the mTORC1 signalling pathways and led to the 
release of EVs with different biomolecular content. These EVs could induce a range of effects in 
recipient cells which promoted changes in the tumour microenvironment that supported tumour 
progression [15]. Dr Clotilde Théry (Institut Curie) described her ground-breaking work on 
characterising the molecular heterogeneity of EVs. She described the contents and different 
biological effects of heterogenous EVs released by dendritic cells [16]. She made an excellent 
analogy between the current field of EVs and the field of immunology a few decades ago. In the field 
of immunology it was recognised that lymphocytes could be divided into different subtypes; after 
many years of painstaking research many of these subtypes have been identified and characterised. 
A similar effort is required in the EV field to identify and study the roles of different vesicular 
subtypes in the tumour microenvironment and more widely in physiology and pathophysiology. 
 
Tumour EVs and the immune system 
Many studies have shown that EVs play an important role in the immune response [17]. The immune 
system is implicated in clearing early-stage tumours, and so one of the hallmarks of cancer that 
progresses is the ability to evade the immune response [7]. As part of this process cancer cells can 
release EVs that may subvert cells of the immune system within the tumour microenvironment [12]. 
Christopher Gregory (MRC Centre for Inflammation Research, The University of Edinburgh) described 
how apoptotic cells in the tumour microenvironment can activate endothelial cells (which in turn 
promote angiogenesis) and macrophages, both of which then support the tumour in what Prof 
Gregory terms the ‘onco-regenerative niche’ [18]. Professor Elke Pogge von Strandmann (University 
of Cologne, Germany) showed that by activating the retinoic acid-inducible gene I in malignant B 
cells EVs were released with the ability to trigger natural killer cells to kill the tumour cells [19]. This 
highlights the complex cross-talk between the tumour and the immune system and how it could 
potentially be targeted or therapeutic benefit. Dr Muller Fabbri (University of Southern California, 
USA) described his seminal work on non-canonical functions of miRNAs. He showed that miRNAs 
don’t always act in the classically described way (by silencing gene expression) but can also act as 
ligands to RNA binding proteins such as Toll-like receptors (TLRs) [20]. He described how miRNAs 
released by tumour cells can act as hormones within the tumour microenvironment, binding to TLR8 
in TAMs. These TAMs in turn release EVs carrying miRNAs that, when taken up by the tumour cells, 
induce tumour progression and drug resistance [21]. 
 
EVs in the tumour microenvironment 
Other examples of how EVs modulate cross talk within the tumour microenvironment were also 
described. Dr Michael Graner (University of Colorado Denver) showed that glioblastoma cells can 
release EVs that activate astrocytes, cells that can support neuron function. These activated 
astrocytes can migrate towards the tumour cells and release various factors that support the growth 
of the tumour. Dr Ana O'Loghlen (Queen Mary, University of London) presented her work on 
senescent cells. When cells age or accrue damage to their DNA they can become senescent, a state 
in which the cells are metabolically active but are no longer able to divide. Dr O’Loghlen showed 
here that during senescence the tumour cells secrete EVs that can influence tumour cells and other 
stromal cells in the tumour microenvironment. Professor Mattias Belting (Lund University) has 
published seminal work on the pathways of EV uptake and the effects of hypoxia on EV function 
within the tumour microenvironment [22, 23]. Here Prof Belting presented his latest work on how 
the regulation of EV uptake and release can affect tumour aggressiveness and how this could 
represent an important therapeutic target. Dr Junko Ohyashiki (Tokyo Medical University) described 
how hypoxic multiple myeloma can release EVs carrying miRNAs able to induce angiogenesis [24]. Dr 
Miki De Palma (École Polytechnique Eédérale de Lausanne) showed how EVs released by cells 
treated with paclitaxel (a microtubule-stabilising agent) can affect metastatic colonisation in breast 
cancer. Dr Hector Peinado (Spanish National Cancer Centre) described how EVs released by tumour 
cells can reprogram stromal cells, including in the lymphatic system. These changes lead to the 
formation of a pre-metastatic niche, which facilitates the metastatic spread of the tumour to lymph 
nodes. 
 
 
 
EVs as biomarkers in the tumour microenvironment 
The accessibility of EVs in many different biofluids makes them ideal biomarkers for the diagnosis 
and prognosis of tumours [25]. Early diagnosis provides one of the best ways of improving survival in 
cancer, so developing new biomarkers for the disease should be a priority. Dr Stuart Hunt (University 
of Sheffield) described how EVs released by head and neck cancer cells into the tumour 
microenvironment could be harnessed as biomarkers in ‘liquid biopsies’ for earlier detection of 
tumours. Future work is needed to expand on this and test the potential of EVs as biomarkers. 
 
Conclusion 
These examples of cross-talk between cancer and the tumour microenvironment represent 
significant examples of an emerging field. Further work is required to fully elucidate the nature and 
extent of this cross-talk, as well as exploring the therapeutic and diagnostic potential of tapping into 
this ongoing dialogue in the tumour microenvironment. We hope that this vibrant meeting and this 
special edition of Philosophical Transactions of the Royal Society B will provide a stimulus to 
researchers studying the role of EVs in the tumour microenvironment. 
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